Investigation and management of residual sleepiness in CPAP-treated patients with obstructive sleep apnoea: the European view

Excessive daytime sleepiness (EDS) is a major symptom of obstructive sleep apnoea (OSA), defined as the inability to stay awake during the day. Its clinical descriptors remain elusive, and the pathogenesis is complex, with disorders such as insufficient sleep and depression commonly associated. Subj...

Descripción completa

Detalles Bibliográficos
Autores: Craig, Sonya, Pepin, Jean Louis, Randerath, Winfried, Caussé, Christian, Verbraecken, Johan, Asin, Jerryll, Barbé Illa, Ferran, Bonsignore, Maria R.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10459.1/84367
Acceso en línea:https://doi.org/10.1183/16000617.0230-2021
http://hdl.handle.net/10459.1/84367
Access Level:acceso abierto
Palabra clave:Son--Pacients
Síndromes d'apnea del son
id ES_bbfa127feef0bb9bcfcf28eea1b5c151
oai_identifier_str oai:recercat.cat:10459.1/84367
network_acronym_str ES
network_name_str España
repository_id_str
spelling Investigation and management of residual sleepiness in CPAP-treated patients with obstructive sleep apnoea: the European viewCraig, SonyaPepin, Jean LouisRanderath, WinfriedCaussé, ChristianVerbraecken, JohanAsin, JerryllBarbé Illa, FerranBonsignore, Maria R.Son--PacientsSíndromes d'apnea del sonExcessive daytime sleepiness (EDS) is a major symptom of obstructive sleep apnoea (OSA), defined as the inability to stay awake during the day. Its clinical descriptors remain elusive, and the pathogenesis is complex, with disorders such as insufficient sleep and depression commonly associated. Subjective EDS can be evaluated using the Epworth Sleepiness Scale, in which the patient reports the probability of dozing in certain situations; however, its reliability has been challenged. Objective tests such as the multiple sleep latency test or the maintenance of wakefulness test are not commonly used in patients with OSA, since they require nocturnal polysomnography, daytime testing and are expensive. Drugs for EDS are available in the United States but were discontinued in Europe some time ago. For European respiratory physicians, treatment of EDS with medication is new and they may lack experience in pharmacological treatment of EDS, while novel wake-promoting drugs have been recently developed and approved for clinical use in OSA patients in the USA and Europe. This review will discuss 1) the potential prognostic significance of EDS in OSA patients at diagnosis, 2) the prevalence and predictors of residual EDS in treated OSA patients, and 3) the evolution of therapy for EDS specifically for Europe.European Respiratory Society202220222022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://doi.org/10.1183/16000617.0230-2021http://hdl.handle.net/10459.1/84367http://hdl.handle.net/10459.1/84367reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a https://doi.org/10.1183/16000617.0230-2021European Respiratory Review, 2022, vol. 31, núm. 164, art. 210230cc-by-nc (c) Sonya Craig et. al., 2022info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc/4.0/oai:recercat.cat:10459.1/843672026-05-29T05:05:01Z
dc.title.none.fl_str_mv Investigation and management of residual sleepiness in CPAP-treated patients with obstructive sleep apnoea: the European view
title Investigation and management of residual sleepiness in CPAP-treated patients with obstructive sleep apnoea: the European view
spellingShingle Investigation and management of residual sleepiness in CPAP-treated patients with obstructive sleep apnoea: the European view
Craig, Sonya
Son--Pacients
Síndromes d'apnea del son
title_short Investigation and management of residual sleepiness in CPAP-treated patients with obstructive sleep apnoea: the European view
title_full Investigation and management of residual sleepiness in CPAP-treated patients with obstructive sleep apnoea: the European view
title_fullStr Investigation and management of residual sleepiness in CPAP-treated patients with obstructive sleep apnoea: the European view
title_full_unstemmed Investigation and management of residual sleepiness in CPAP-treated patients with obstructive sleep apnoea: the European view
title_sort Investigation and management of residual sleepiness in CPAP-treated patients with obstructive sleep apnoea: the European view
dc.creator.none.fl_str_mv Craig, Sonya
Pepin, Jean Louis
Randerath, Winfried
Caussé, Christian
Verbraecken, Johan
Asin, Jerryll
Barbé Illa, Ferran
Bonsignore, Maria R.
author Craig, Sonya
author_facet Craig, Sonya
Pepin, Jean Louis
Randerath, Winfried
Caussé, Christian
Verbraecken, Johan
Asin, Jerryll
Barbé Illa, Ferran
Bonsignore, Maria R.
author_role author
author2 Pepin, Jean Louis
Randerath, Winfried
Caussé, Christian
Verbraecken, Johan
Asin, Jerryll
Barbé Illa, Ferran
Bonsignore, Maria R.
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Son--Pacients
Síndromes d'apnea del son
topic Son--Pacients
Síndromes d'apnea del son
description Excessive daytime sleepiness (EDS) is a major symptom of obstructive sleep apnoea (OSA), defined as the inability to stay awake during the day. Its clinical descriptors remain elusive, and the pathogenesis is complex, with disorders such as insufficient sleep and depression commonly associated. Subjective EDS can be evaluated using the Epworth Sleepiness Scale, in which the patient reports the probability of dozing in certain situations; however, its reliability has been challenged. Objective tests such as the multiple sleep latency test or the maintenance of wakefulness test are not commonly used in patients with OSA, since they require nocturnal polysomnography, daytime testing and are expensive. Drugs for EDS are available in the United States but were discontinued in Europe some time ago. For European respiratory physicians, treatment of EDS with medication is new and they may lack experience in pharmacological treatment of EDS, while novel wake-promoting drugs have been recently developed and approved for clinical use in OSA patients in the USA and Europe. This review will discuss 1) the potential prognostic significance of EDS in OSA patients at diagnosis, 2) the prevalence and predictors of residual EDS in treated OSA patients, and 3) the evolution of therapy for EDS specifically for Europe.
publishDate 2022
dc.date.none.fl_str_mv 2022
2022
2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://doi.org/10.1183/16000617.0230-2021
http://hdl.handle.net/10459.1/84367
http://hdl.handle.net/10459.1/84367
url https://doi.org/10.1183/16000617.0230-2021
http://hdl.handle.net/10459.1/84367
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a https://doi.org/10.1183/16000617.0230-2021
European Respiratory Review, 2022, vol. 31, núm. 164, art. 210230
dc.rights.none.fl_str_mv cc-by-nc (c) Sonya Craig et. al., 2022
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc/4.0/
rights_invalid_str_mv cc-by-nc (c) Sonya Craig et. al., 2022
http://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv European Respiratory Society
publisher.none.fl_str_mv European Respiratory Society
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869418072912166912
score 15,811543

Similares en LA Referencia